Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Clinical trial NCT06453044 · RECRUITING

Trial details

NCT number: NCT06453044
Sponsor: City of Hope Medical Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Refractory Grade 1 Follicular Lymphoma Refractory Grade 2 Follicular Lymphoma Refractory Grade 3a Follicular Lymphoma

Start date: 2024-09-09
Primary completion: 2028-03-14
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.